Bausch Health Discusses Strategic Options for Bausch + Lomb
During its third-quarter 2026 earnings call, Bausch Health Companies Inc. addressed potential strategic options regarding its ownership stake in Bausch + Lomb Corporation.
Stocks · News reference
HC Wainwright Downgrades Bausch + Lomb to Neutral from Buy
HC Wainwright & Co. has downgraded Bausch + Lomb Corporation from Buy to Neutral while increasing its price target to $22 from $21.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bausch + Lomb SVP and CAO Frederick Munsch Sells Shares
Frederick Munsch, Senior Vice President, Controller, and Chief Accounting Officer of Bausch + Lomb, sold 112,015 common shares for approximately $2.29 million.
FactSet Analyst Survey Updates Bausch + Lomb EPS Forecast and Price Target
A recent survey of 14 analysts by FactSet has resulted in an upward revision of Bausch + Lomb Corporation's 2026 earnings per share (EPS) estimate and price target.
Wells Fargo Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $19
Analysts Raise Price Targets for Bausch + Lomb Following Q3 Earnings
Multiple financial institutions, including RBC, Leerink Partners, and Jefferies, increased their price targets for Bausch + Lomb on October 29, 2026, following the company's third-quarter earnings report.
Bausch + Lomb Announces Publication of Multinational Survey Results on Dry Eye
Bausch + Lomb has published findings from a multinational survey that examines consumer perspectives, symptoms, and interactions with healthcare professionals regarding dry eye.